Lionco Pharmaceutical Group Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Lingkang Pharmaceutical Group Co., Ltd. is an innovative enterprise group that integrates pharmaceutical research and development, production, sales, and medical services. Since its establishment in 2003, it has always adhered to the corporate philosophy of "agility, wisdom, and focus on health". After more than ten years of entrepreneurial development, it was listed on the Shanghai Stock Exchange in May 2015 (stock code 603669). The Group has five major pharmaceutical production bases, three major pharmaceutical research institutes and several pharmaceutical sales companies. Its subsidiaries are mainly located in Tibet, Zhejiang, Hainan, Sichuan and other provinces and regions. It has successively won the honors of "National High tech Enterprise", "China's New Industrialization Contribution Award", "China's Patent Excellence Award", "exemplary organization for the Implementation of Brand Strategy", "China's Innovative Pharmaceutical Enterprise", etc, Ranked on the "Top 100 Comprehensive Strength Rankings of China's Drug Research and Development". |
| Headquarter | Shannan City |
| Establish Date | 12/24/2003 |
| Listed Code | 603669.SH |
| Listed Date | 5/28/2015 |
| Chairman | Tao Lingping. |
| CEO | Tao Lingping. |
| Website | www.lingkang.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
